Christine Dacier, MD
Family Medicine · New Britain, PANPI 1659300721
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,560 of the $6,335 with a category attached, or 72.0%. Genentech USA, Inc. accounts for 96.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $6,136 and has fallen 99.3% since, to $43 in 2025. Among family medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 16 payments — averaging $395.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$6K
- GSK$46
- AbbVie$34
- Amgen$31
- Inspire Medical Systems, Inc.$24
- Vertos Medical, Inc.$18
- plus $81 from 5 others
What the payments were for
- Consulting fees$4,56072%
- Travel & lodging$1,54124%
- Food & beverage$2344%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 2 | $6,101 |
| GSK | 3 | $46 |
| AbbVie | 2 | $34 |
| Amgen | 2 | $31 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Vertos Medical, Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Merck | 1 | $16 |
| Medtronic | 1 | $15 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$6,101
How this compares
$6,335 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 38 | $26,298 |
| TrulicityDulaglutide | 16 | $15,437 |
| JardianceEmpagliflozin | 19 | $14,469 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,762 |
| Rosuvastatin Calcium | 374 | $4,687 |
| Atorvastatin Calcium | 317 | $4,375 |
| Losartan Potassium | 253 | $3,475 |
| Enalapril Maleate | 122 | $2,505 |
| Levothyroxine Sodium | 238 | $2,430 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,704 |
| Fluticasone Propionate | 60 | $1,611 |
| SynthroidLevothyroxine Sodium | 26 | $1,327 |
| Diltiazem 12hr ErDiltiazem Hcl | 15 | $1,272 |
| Metoprolol Succinate | 76 | $1,179 |
| Methylphenidate ErMethylphenidate Hcl | 11 | $1,163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $46 | $7,76212 claims |
| AbbVieSynthroid | $34 | $1,32726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in New Britain
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
- Deborah WittPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.